First International Workshop on the Biology Prevention and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
Relapse is a major cause of treatment failure after allogeneic hematopoietic stem cell transplantation (alloHSCT) Treatment options for relapse have been inadequate and the majority of patients ultimately die of their disease. There is no standard approach to treating relapse after alloHSCT. Withdrawal of immune suppression and donor lymphocyte infusions (DLI) are commonly used for all diseases; although these interventions are remarkably effective for relapsed CML, they have limited efficacy in other hematologic malignancies. Conventional and novel chemotherapy, monoclonal antibody therapy, targeted therapies, and second transplants have been utilized in a variety of relapsed diseases, but reports on these therapies are generally anecdotal and retrospective. As such there is an immediate need for well designed, disease specific trials for treatment of relapse after alloHSCT. This report summarizes current treatment options under investigation for relapse after alloHSCT in a disease specific manner. In addition, recommendations are provided for specific areas of research necessary in the treatment of relapse after alloHSCT. (c) 2010 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved. Corresponding author: David L. Porter, M.D. Division of Hematology Oncology, University of Pennsylvania Medical Center, PCAM 2 West Pavilion, 3400 Civic Center Blvd, Philadelphia, PA, USA, david.porter@uphs.upenn.edu, Phone: 215 662 2862, Fax: 215 615 5888. *All authors contributed equally to this work. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. NIH Public Access Author Manuscript Biol Blood Marrow Transplant. Author manuscript; available in PMC 2011 November 1. Published in final edited form as: Biol Blood Marrow Transplant. 2010 November 16(11) 1467 1503. doi:10.1016/j.bbmt.2010.08.001. N IH PA Athor M anscript N IH PA Athor M anscript N IH PA Athor M anscript